Skip to content

Study · Not a test of the peptide alone · 1997

3 results

Attenuation of the growth hormone secretagogue induction of Fos protein in the rat arcuate nucleus by central somatostatin action.

Dickson SL, Viltart O, Bailey AR, Leng G

Neuroendocrinology1 Sept 1997Cited by 28 (Europe PMC)

PMID9380276 (opens in a new tab)DOI10.1159/000127237 (opens in a new tab)PepBankPUB-09380276
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism

    In rats, intravenous sandostatin reduced GHRP‑6-induced arcuate Fos-positive nuclei compared with saline pretreatment.

    In plain wordsIn rats, intravenous sandostatin reduced GHRP‑6-induced Fos-positive nuclei compared with saline pretreatment.

    Peptide
    GHRP-6
    Outcome
    DecreaseFos-positive nuclei after intravenous sandostatin
    Study

    ratn: not reported in source

    Comparator
    intravenous saline before GHRP-6
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Measurements

    Fos-positive nuclei
    28 nuclei/section
    sandostatin/GHRP-6
    Fos-positive nuclei
    56 nuclei/section
    saline/GHRP-6

    Source sentences

    Summary
    The number of Fos-positive nuclei detected in the arcuate nucleus of the i.v. sandostatin/i.v. GHRP-6 treated rats (28 +/- 5 nuclei/section) and the i.v. sandostatin/i.v. MK-0677-injected rats (8 +/- 2 nuclei/section)
    3 context sentences
    Summary · context
    was significantly less than the i.v. saline/i.v. GHRP-6-treated group (56 +/- 5 nuclei/section) and the i.v. saline/ i.v. MK-0677-treated group (20 +/- 2 nuclei/section) respectively.
    Summary · context
    Conscious male rats were injected i.v. with 100 micrograms sandostatin (octreotide, a long-acting somatostatin analogue) or saline, 10 min before an i.v. injection of either 50 micrograms GH-releasing peptide (GHRP-6), 50 micrograms MK-0677 (a non-peptide GH secretagogue) or saline.
    Summary · context
    In all studies, rats were anaesthetized 90 min following GH secretagogue injection, perfused with fixative and the brains processed for the immunocytochemical detection of Fos protein.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 02AnimalNot a test of MK-677 (ibutamoren) aloneAnimal study (in vivo)Mechanism

    In rats, intravenous sandostatin reduced MK-0677-induced arcuate Fos-positive nuclei compared with saline pretreatment.

    In plain wordsIn rats, intravenous sandostatin reduced MK-0677-induced Fos-positive nuclei compared with saline pretreatment.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    DecreaseFos-positive nuclei after intravenous sandostatin
    Study

    ratn: not reported in source

    Comparator
    intravenous saline before MK-0677
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Measurements

    Fos-positive nuclei
    8 nuclei/section
    sandostatin/MK-0677
    Fos-positive nuclei
    20 nuclei/section
    saline/MK-0677

    Source sentences

    Summary
    The number of Fos-positive nuclei detected in the arcuate nucleus of the i.v. sandostatin/i.v. GHRP-6 treated rats (28 +/- 5 nuclei/section) and the i.v. sandostatin/i.v. MK-0677-injected rats (8 +/- 2 nuclei/section)
    3 context sentences
    Summary · context
    was significantly less than the i.v. saline/i.v. GHRP-6-treated group (56 +/- 5 nuclei/section) and the i.v. saline/ i.v. MK-0677-treated group (20 +/- 2 nuclei/section) respectively.
    Summary · context
    Conscious male rats were injected i.v. with 100 micrograms sandostatin (octreotide, a long-acting somatostatin analogue) or saline, 10 min before an i.v. injection of either 50 micrograms GH-releasing peptide (GHRP-6), 50 micrograms MK-0677 (a non-peptide GH secretagogue) or saline.
    Summary · context
    In all studies, rats were anaesthetized 90 min following GH secretagogue injection, perfused with fixative and the brains processed for the immunocytochemical detection of Fos protein.

    In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).

  3. 03AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism

    In rats, central sandostatin reduced GHRP‑6-induced Fos-positive nuclei compared with aCSF pretreatment.

    In plain wordsIn rats, central sandostatin reduced GHRP‑6-induced Fos-positive nuclei compared with aCSF pretreatment.

    Peptide
    GHRP-6
    Outcome
    DecreaseFos-positive nuclei after central sandostatin
    Study

    ratn: not reported in source

    Comparator
    intracerebroventricular aCSF before GHRP-6
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Measurements

    Fos-positive nuclei
    53 nuclei/section
    aCSF/GHRP-6
    Fos-positive nuclei
    39 nuclei/section
    sandostatin/GHRP-6

    Source sentences

    Summary
    Intracerebroventricular sandostatin injection attenuated the GHRP-6-induced Fos response, from 53 +/- 6 nuclei/section in the i.c.v. aCSF/i.v. GHRP-6 group, to 39 +/- 5 nuclei/section in the i.c.v. sandostatin/i.v. GHRP-6 group.
    3 context sentences
    Summary · context
    In a separate study, conscious male rats were injected i.c.v. with either 2 micrograms sandostatin or artificial cerebrospinal fluid (aCSF) vehicle 20 min before an i.v. injection of 50 micrograms GHRP-6.
    Summary · context
    Conscious male rats were injected i.v. with 100 micrograms sandostatin (octreotide, a long-acting somatostatin analogue) or saline, 10 min before an i.v. injection of either 50 micrograms GH-releasing peptide (GHRP-6), 50 micrograms MK-0677 (a non-peptide GH secretagogue) or saline.
    Summary · context
    In all studies, rats were anaesthetized 90 min following GH secretagogue injection, perfused with fixative and the brains processed for the immunocytochemical detection of Fos protein.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 2

    14 Oct 2026, 01:46 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.